Company Overview of ZymoGenetics Inc.
ZymoGenetics Inc., a biopharmaceutical company, develops and commercializes therapeutic proteins for the treatment of human diseases. It provides RECOTHROM Thrombin, a topical recombinant in the United States; PEG-Interferon lambda for treatment of hepatitis C virus infection; IL-21 for treatment of metastatic melanoma; and anti-IL-31 monoclonal antibody for treatment of atopic dermatitis. ZymoGenetics Inc. was formerly known as Zymos and changed its name to ZymoGenetics Inc. in 1983. The company was founded in 1981 and is headquartered in Seattle, Washington. As of October 7, 2010, ZymoGenetics Inc. operates as a subsidiary of Bristol-Myers Squibb Company.
1201 Eastlake Avenue East
Seattle, WA 98102-3702
Founded in 1981
Key Executives for ZymoGenetics Inc.
Similar Private Companies By Industry
|Cira Discovery Sciences, Inc.||United States|
|Bartels, Inc.||United States|
|Dainippon Sumitomo Pharma America Holdings, Inc.||United States|
|Verichem Laboratories, Inc.||United States|
|Epizyme, Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|NYC2012, Inc.||United States|
|Lawyers Committee for Civil Rights Under Law||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Post a JobJobs
- Boston, MA | PwCPosted: Aug 28
- Madison, WI | Madison Area Technical CollegePosted: May 23
- Tarrytown, NY | BASFPosted: May 22
- San Francisco, CA | Confidential Biotechnology CompanyPosted: May 13
Sponsored Financial Commentaries
To contact ZymoGenetics Inc., please visit www.zymogenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.